NextCell Pharma AB (NXTCL) AI Stock Analysis

NextCell Pharma AB

(Nasdaq OMX AB:NXTCL)

Select Model

Rating:49Neutral

Price Target:SEK 1.00▲(334.78% Upside)

Action:reiterated

Date:09/10/26

Overall score reflects very weak financial performance driven by persistent losses and heavy cash burn, partially offset by the absence of debt. Technicals are neutral with price above key moving averages but muted momentum (slightly negative MACD and neutral RSI). Valuation is difficult to support because earnings are negative (negative P/E) and no dividend yield is available.

Positive Factors

Debt-free balance sheetThe absence of reported debt reduces refinancing pressure and interest-related financial risk, giving NextCell greater flexibility during development cycles. A debt-free structure can also preserve access to future financing options, although it does not offset the company’s current cash-burn challenges.

Negative Factors

Persistent cash burnSustained negative operating and free cash flow means the business is consuming cash rather than funding operations internally. This can require repeated capital raising or other financing, potentially limiting strategic flexibility and increasing dilution or funding pressure during ongoing clinical development.

NextCell Pharma AB (NXTCL) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 29.07M
Dividend Yield: ―
Average Volume (3M): 643.72K
Price to Earnings (P/E): -0.6
Beta (1Y): 0.20
Revenue Growth: -4.02%
EPS Growth: 35.86%
Country: Sweden
Employees: 24
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

NextCell Pharma AB Business Overview & Revenue Model

Company Description

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investig...

NextCell Pharma AB Financial Statement Overview

Summary

Financials are weak overall: despite revenue growth (8.28% TTM), gross profit remains deeply negative (TTM gross loss ~45.2M on ~10.1M revenue) and net losses are large (~44.5M TTM). The key offsetting strength is no reported debt, but equity has fallen materially over time (from ~150.1M in 2021 to ~47.1M TTM) and cash burn remains significant (operating cash flow ~-53.0M TTM; free cash flow ~-57.7M TTM).

Income Statement

18Very Negative

Balance Sheet

56Neutral

Cash Flow

22Negative

Financial statement breakdown
Breakdown	TTM	Aug 2025	Aug 2024	Aug 2023	Aug 2022	Aug 2021
Income Statement
Total Revenue	10.09M	10.94M	10.66M	10.11M	5.59M	3.91M
Gross Profit	-45.17M	-35.87M	-4.56M	-884.83K	-22.26M	-14.53M
EBITDA	-42.47M	-32.63M	-40.99M	-39.36M	-34.10M	-24.21M
Net Income	-44.48M	-35.14M	-41.96M	-39.81M	-34.08M	-24.56M
Balance Sheet
Total Assets	63.90M	76.73M	81.29M	88.83M	124.66M	155.63M
Cash, Cash Equivalents and Short-Term Investments	21.09M	38.72M	46.79M	50.03M	97.12M	139.17M
Total Debt	0	0	0	0	0	0
Total Liabilities	16.83M	10.34M	13.69M	13.10M	9.12M	5.53M
Stockholders Equity	47.07M	66.39M	67.60M	75.73M	115.54M	150.09M
Cash Flow
Free Cash Flow	-57.71M	-43.05M	-37.86M	-47.92M	-40.90M	-26.30M
Operating Cash Flow	-52.97M	-38.86M	-37.78M	-43.83M	-33.31M	-25.58M
Investing Cash Flow	-5.00M	-4.24M	-83.51K	-4.10M	-9.37M	-5.84M
Financing Cash Flow	84.36M	35.03M	34.63M	835.66K	608.17K	148.63M

NextCell Pharma AB Technical Analysis

Technical Analysis SentimentNegative

Last Price0.23

Price Trends

50DMA0.98Negative

100DMA1.01Negative

200DMA1.15Negative

Market Momentum

MACD-0.19Positive

RSI17.06Positive

STOCH3.66Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NXTCL, the sentiment is Negative. The current price of 0.23 is below the 20-day moving average (MA) of 0.83, below the 50-day MA of 0.98, and below the 200-day MA of 1.15, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 17.06 is Positive, neither overbought nor oversold. The STOCH value of 3.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NXTCL.

NextCell Pharma AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:NXTCL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:FLUI	55Neutral	SEK 38.33M	13.65	21.37%	―	837.37%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:NXTCL	49Neutral	SEK 29.07M	-0.60	-81.23%	―	-4.02%	35.86%
SE:ELIC	48Neutral	SEK 177.19M	-7.51	-56.09%	―	―	14.10%
SE:IMMU	43Neutral	SEK 348.89M	-3.07	-18.05%	―	―	15.97%
SE:ANNX	42Neutral	SEK 57.89M	-1.51	―	―	―	7.33%
SE:XINT	39Underperform	SEK 134.36M	-2.67	245.07%	―	-38.46%	9.02%

* Healthcare Sector Average

Performance Comparison

SE:NXTCL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:NXTCL	NextCell Pharma AB	0.23	-0.66	-74.16%
SE:XINT	Xintela AB	0.16	-0.28	-63.97%
SE:ELIC	Elicera Therapeutics AB	2.65	-3.44	-56.47%
SE:IMMU	Immunicum AB	5.50	-1.89	-25.58%
SE:FLUI	Fluicell AB	27.90	14.90	114.62%
SE:ANNX	Annexin Pharmaceuticals AB	6.64	-19.56	-74.66%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 10, 2026

NextCell Pharma AB AI Stock Analysis